共 50 条
- [41] Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancerCANCER RESEARCH, 2022, 82 (04)Torres, AlexandraKokkonen, CareyOladeji, MaryD'Andrea, KurtMick, RosemarieNarayan, VivekMallamaci, MichaelEwing, GayleKnollman, HayleyTung, Nadine M.Robson, MarkNathanson, Katherine L.Domchek, SusanShah, Payal D.
- [42] Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancerBreast Cancer Research and Treatment, 2021, 188 : 799 - 809Kristoffer B. KristensenIda Marie Nedergaard ThomsenTobias BergAnnette R. KodahlAnders Bonde Jensen
- [43] Patient-specific circulating tumor DNA detection during palbociclib/fulvestrant therapy in HR+/HER2-metastatic breast cancerCLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (03) : 188 - 189Darrigues, L.Proudhon, C.Bidard, F. C.
- [44] Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2-metastatic breast cancer patientsCANCER RESEARCH, 2022, 82 (04)Polimera, Hyma V.Bhatt, DhirishaShepherd, Lois E.Gelmon, KarenJoy, Anil A.Parulekar, Wendy R.Joshi, MonikaAli, Suhail M.Leitzel, KimTruica, CristinaVasekar, MonaliDrabick, Joseph J.Menon, HarryShah, NealMaddukuri, AshokMoku, PrashanthHalstead, E. ScottMcKeone, DanielUmstead, Todd M.Chen, B. E.Lipton, Allan
- [45] Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2-Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese PopulationTECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21Zhang, YusiChen, WenlinChen, ShuanglongYang, QingmoOuyang, Zhong
- [46] Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2-metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional studyINTERNATIONAL JOURNAL OF CANCER, 2022, 150 (12) : 2025 - 2037Ha, Min JinRaghavendra, Akshara SingareekaKettner, Nicole M.Qiao, WeiDamodaran, SenthilLayman, Rachel M.Hunt, Kelly K.Shen, YuTripathy, DebuKeyomarsi, Khandan
- [47] Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2-metastatic breast cancerEUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (09) : 1387 - 1397Pan, MeiyuLin, YanLiu, YinhuiXu, RuijuanYang, Jin
- [48] Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2-metastatic breast cancer: A single center real-world study in ChinaCANCER MEDICINE, 2024, 13 (10):Jiang, HanfangZhong, JianxinWang, JingSong, GuohongDi, LijunShao, BinZhang, RuyanLiu, YaxinZhu, AnjieWang, NanLi, Huiping
- [49] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER, part 1)CANCER RESEARCH, 2022, 82 (04)Spring, Laura M.Scarpetti, LaurenNiemierko, AndrzejIsakoff, Steven J.Moy, BeverlyWander, Seth A.Smith, ElisabethAbraham, ElizabethShin, JenniferPatel, Jaymin M.Comander, AmyMulvey, ThereseBardia, Aditya
- [50] The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitorsCANCER RESEARCH, 2023, 83 (05)Kamaraju, SailajaFowler, AmyChaudhary, Lubna N.Burkard, MarkGiever, ThomasHegeman, Robert N.Pipp-Dahm, MicheleCheng, Yee ChungLange, CarolJorns, Julie M.Stella, AmySiddiqui, NaumanZurbriggen, LukeRajguru, SaurabhTarima, SergeySriram, DeepikaRetseck, JanetRui, HallgeirSahmoud, TarekWisinski, Kari B.